Gathering momentum for the way ahead

fifth report of the Lancet Standing Commission on Liver Disease in the UK

Roger Williams, Graeme Alexander, Richard Aspinall, Rachel Batterham, Neeraj Bhala, Nick Bosanquet, Katherine Severi, Anya Burton, Robyn Burton, Matthew E. Cramp, Natalie Day, Anil Dhawan, John Dillon, Colin Drummond, Jessica Dyson, James Ferguson, Graham R. Foster, Ian Gilmore, Jonny Greenberg, Clive Henn & 19 others Mark Hudson, Helen Jarvis, Deirdre Kelly, Jake Mann, Neil McDougall, Martin McKee, Kieran Moriarty, Joanne Morling, Philip Newsome, John O'Grady, Liz Rolfe, Peter Rice, Harry Rutter, Nick Sheron, Douglas Thorburn, Julia Verne, Jyotsna Vohra, John Wass, Andrew Yeoman

Research output: Contribution to journalComment/debate

14 Citations (Scopus)
21 Downloads (Pure)

Abstract

This report presents further evidence on the escalating alcohol consumption in the UK and the burden of liver disease associated with this major risk factor, as well as the effects on hospital and primary care. We reiterate the need for fiscal regulation by the UK Government if overall alcohol consumption is to be reduced sufficiently to improve health outcomes. We also draw attention to the effects of drastic cuts in public services for alcohol treatment, the repeated failures of voluntary agreements with the drinks industry, and the influence of the industry through its lobbying activities. We continue to press for reintroduction of the alcohol duty escalator, which was highly effective during the 5 years it was in place, and the introduction of minimum unit pricing in England, targeted at the heaviest drinkers. Results from the introduction of minimum unit pricing in Scotland, with results from Wales to follow, are likely to seriously expose the weakness of England's position. The increasing prevalence of obesity-related liver disease, the rising number of people diagnosed with type 2 diabetes and its complications, and increasing number of cases of end-stage liver disease and primary liver cancers from non-alcoholic fatty liver disease make apparent the need for an obesity strategy for adults. We also discuss the important effects of obesity and alcohol on disease progression, and the increased risk of the ten most common cancers (including breast and colon cancers). A new in-depth analysis of the UK National Health Service (NHS) and total societal costs shows the extraordinarily large expenditures that could be saved or redeployed elsewhere in the NHS. Excellent results have been reported for new antiviral drugs for hepatitis C virus infection, making elimination of chronic infection a real possibility ahead of the WHO 2030 target. However, the extent of unidentified cases remains a problem, and will also apply when new curative drugs for hepatitis B virus become available. We also describe efforts to improve standards of hospital care for liver disease with better understanding of current service deficiencies and a new accreditation process for hospitals providing liver services. New commissioning arrangements for primary and community care represent progress, in terms of effective screening of high-risk subjects and the early detection of liver disease.

Original languageEnglish
Pages (from-to)2398-2412
Number of pages15
JournalThe Lancet
Volume392
Issue number10162
Early online date22 Nov 2018
DOIs
Publication statusPublished - 1 Dec 2018

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Williams, R., Alexander, G., Aspinall, R., Batterham, R., Bhala, N., Bosanquet, N., ... Yeoman, A. (2018). Gathering momentum for the way ahead: fifth report of the Lancet Standing Commission on Liver Disease in the UK. The Lancet, 392(10162), 2398-2412. https://doi.org/10.1016/S0140-6736(18)32561-3

Gathering momentum for the way ahead : fifth report of the Lancet Standing Commission on Liver Disease in the UK. / Williams, Roger; Alexander, Graeme; Aspinall, Richard; Batterham, Rachel; Bhala, Neeraj; Bosanquet, Nick; Severi, Katherine; Burton, Anya; Burton, Robyn; Cramp, Matthew E.; Day, Natalie; Dhawan, Anil; Dillon, John; Drummond, Colin; Dyson, Jessica; Ferguson, James; Foster, Graham R.; Gilmore, Ian; Greenberg, Jonny; Henn, Clive; Hudson, Mark; Jarvis, Helen; Kelly, Deirdre; Mann, Jake; McDougall, Neil; McKee, Martin; Moriarty, Kieran; Morling, Joanne; Newsome, Philip; O'Grady, John; Rolfe, Liz; Rice, Peter; Rutter, Harry; Sheron, Nick; Thorburn, Douglas; Verne, Julia; Vohra, Jyotsna; Wass, John; Yeoman, Andrew.

In: The Lancet, Vol. 392, No. 10162, 01.12.2018, p. 2398-2412.

Research output: Contribution to journalComment/debate

Williams, R, Alexander, G, Aspinall, R, Batterham, R, Bhala, N, Bosanquet, N, Severi, K, Burton, A, Burton, R, Cramp, ME, Day, N, Dhawan, A, Dillon, J, Drummond, C, Dyson, J, Ferguson, J, Foster, GR, Gilmore, I, Greenberg, J, Henn, C, Hudson, M, Jarvis, H, Kelly, D, Mann, J, McDougall, N, McKee, M, Moriarty, K, Morling, J, Newsome, P, O'Grady, J, Rolfe, L, Rice, P, Rutter, H, Sheron, N, Thorburn, D, Verne, J, Vohra, J, Wass, J & Yeoman, A 2018, 'Gathering momentum for the way ahead: fifth report of the Lancet Standing Commission on Liver Disease in the UK', The Lancet, vol. 392, no. 10162, pp. 2398-2412. https://doi.org/10.1016/S0140-6736(18)32561-3
Williams R, Alexander G, Aspinall R, Batterham R, Bhala N, Bosanquet N et al. Gathering momentum for the way ahead: fifth report of the Lancet Standing Commission on Liver Disease in the UK. The Lancet. 2018 Dec 1;392(10162):2398-2412. https://doi.org/10.1016/S0140-6736(18)32561-3
Williams, Roger ; Alexander, Graeme ; Aspinall, Richard ; Batterham, Rachel ; Bhala, Neeraj ; Bosanquet, Nick ; Severi, Katherine ; Burton, Anya ; Burton, Robyn ; Cramp, Matthew E. ; Day, Natalie ; Dhawan, Anil ; Dillon, John ; Drummond, Colin ; Dyson, Jessica ; Ferguson, James ; Foster, Graham R. ; Gilmore, Ian ; Greenberg, Jonny ; Henn, Clive ; Hudson, Mark ; Jarvis, Helen ; Kelly, Deirdre ; Mann, Jake ; McDougall, Neil ; McKee, Martin ; Moriarty, Kieran ; Morling, Joanne ; Newsome, Philip ; O'Grady, John ; Rolfe, Liz ; Rice, Peter ; Rutter, Harry ; Sheron, Nick ; Thorburn, Douglas ; Verne, Julia ; Vohra, Jyotsna ; Wass, John ; Yeoman, Andrew. / Gathering momentum for the way ahead : fifth report of the Lancet Standing Commission on Liver Disease in the UK. In: The Lancet. 2018 ; Vol. 392, No. 10162. pp. 2398-2412.
@article{7f61aea6ee1a4d979c27e1fbda28fb31,
title = "Gathering momentum for the way ahead: fifth report of the Lancet Standing Commission on Liver Disease in the UK",
abstract = "This report presents further evidence on the escalating alcohol consumption in the UK and the burden of liver disease associated with this major risk factor, as well as the effects on hospital and primary care. We reiterate the need for fiscal regulation by the UK Government if overall alcohol consumption is to be reduced sufficiently to improve health outcomes. We also draw attention to the effects of drastic cuts in public services for alcohol treatment, the repeated failures of voluntary agreements with the drinks industry, and the influence of the industry through its lobbying activities. We continue to press for reintroduction of the alcohol duty escalator, which was highly effective during the 5 years it was in place, and the introduction of minimum unit pricing in England, targeted at the heaviest drinkers. Results from the introduction of minimum unit pricing in Scotland, with results from Wales to follow, are likely to seriously expose the weakness of England's position. The increasing prevalence of obesity-related liver disease, the rising number of people diagnosed with type 2 diabetes and its complications, and increasing number of cases of end-stage liver disease and primary liver cancers from non-alcoholic fatty liver disease make apparent the need for an obesity strategy for adults. We also discuss the important effects of obesity and alcohol on disease progression, and the increased risk of the ten most common cancers (including breast and colon cancers). A new in-depth analysis of the UK National Health Service (NHS) and total societal costs shows the extraordinarily large expenditures that could be saved or redeployed elsewhere in the NHS. Excellent results have been reported for new antiviral drugs for hepatitis C virus infection, making elimination of chronic infection a real possibility ahead of the WHO 2030 target. However, the extent of unidentified cases remains a problem, and will also apply when new curative drugs for hepatitis B virus become available. We also describe efforts to improve standards of hospital care for liver disease with better understanding of current service deficiencies and a new accreditation process for hospitals providing liver services. New commissioning arrangements for primary and community care represent progress, in terms of effective screening of high-risk subjects and the early detection of liver disease.",
author = "Roger Williams and Graeme Alexander and Richard Aspinall and Rachel Batterham and Neeraj Bhala and Nick Bosanquet and Katherine Severi and Anya Burton and Robyn Burton and Cramp, {Matthew E.} and Natalie Day and Anil Dhawan and John Dillon and Colin Drummond and Jessica Dyson and James Ferguson and Foster, {Graham R.} and Ian Gilmore and Jonny Greenberg and Clive Henn and Mark Hudson and Helen Jarvis and Deirdre Kelly and Jake Mann and Neil McDougall and Martin McKee and Kieran Moriarty and Joanne Morling and Philip Newsome and John O'Grady and Liz Rolfe and Peter Rice and Harry Rutter and Nick Sheron and Douglas Thorburn and Julia Verne and Jyotsna Vohra and John Wass and Andrew Yeoman",
year = "2018",
month = "12",
day = "1",
doi = "10.1016/S0140-6736(18)32561-3",
language = "English",
volume = "392",
pages = "2398--2412",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Masson",
number = "10162",

}

TY - JOUR

T1 - Gathering momentum for the way ahead

T2 - fifth report of the Lancet Standing Commission on Liver Disease in the UK

AU - Williams, Roger

AU - Alexander, Graeme

AU - Aspinall, Richard

AU - Batterham, Rachel

AU - Bhala, Neeraj

AU - Bosanquet, Nick

AU - Severi, Katherine

AU - Burton, Anya

AU - Burton, Robyn

AU - Cramp, Matthew E.

AU - Day, Natalie

AU - Dhawan, Anil

AU - Dillon, John

AU - Drummond, Colin

AU - Dyson, Jessica

AU - Ferguson, James

AU - Foster, Graham R.

AU - Gilmore, Ian

AU - Greenberg, Jonny

AU - Henn, Clive

AU - Hudson, Mark

AU - Jarvis, Helen

AU - Kelly, Deirdre

AU - Mann, Jake

AU - McDougall, Neil

AU - McKee, Martin

AU - Moriarty, Kieran

AU - Morling, Joanne

AU - Newsome, Philip

AU - O'Grady, John

AU - Rolfe, Liz

AU - Rice, Peter

AU - Rutter, Harry

AU - Sheron, Nick

AU - Thorburn, Douglas

AU - Verne, Julia

AU - Vohra, Jyotsna

AU - Wass, John

AU - Yeoman, Andrew

PY - 2018/12/1

Y1 - 2018/12/1

N2 - This report presents further evidence on the escalating alcohol consumption in the UK and the burden of liver disease associated with this major risk factor, as well as the effects on hospital and primary care. We reiterate the need for fiscal regulation by the UK Government if overall alcohol consumption is to be reduced sufficiently to improve health outcomes. We also draw attention to the effects of drastic cuts in public services for alcohol treatment, the repeated failures of voluntary agreements with the drinks industry, and the influence of the industry through its lobbying activities. We continue to press for reintroduction of the alcohol duty escalator, which was highly effective during the 5 years it was in place, and the introduction of minimum unit pricing in England, targeted at the heaviest drinkers. Results from the introduction of minimum unit pricing in Scotland, with results from Wales to follow, are likely to seriously expose the weakness of England's position. The increasing prevalence of obesity-related liver disease, the rising number of people diagnosed with type 2 diabetes and its complications, and increasing number of cases of end-stage liver disease and primary liver cancers from non-alcoholic fatty liver disease make apparent the need for an obesity strategy for adults. We also discuss the important effects of obesity and alcohol on disease progression, and the increased risk of the ten most common cancers (including breast and colon cancers). A new in-depth analysis of the UK National Health Service (NHS) and total societal costs shows the extraordinarily large expenditures that could be saved or redeployed elsewhere in the NHS. Excellent results have been reported for new antiviral drugs for hepatitis C virus infection, making elimination of chronic infection a real possibility ahead of the WHO 2030 target. However, the extent of unidentified cases remains a problem, and will also apply when new curative drugs for hepatitis B virus become available. We also describe efforts to improve standards of hospital care for liver disease with better understanding of current service deficiencies and a new accreditation process for hospitals providing liver services. New commissioning arrangements for primary and community care represent progress, in terms of effective screening of high-risk subjects and the early detection of liver disease.

AB - This report presents further evidence on the escalating alcohol consumption in the UK and the burden of liver disease associated with this major risk factor, as well as the effects on hospital and primary care. We reiterate the need for fiscal regulation by the UK Government if overall alcohol consumption is to be reduced sufficiently to improve health outcomes. We also draw attention to the effects of drastic cuts in public services for alcohol treatment, the repeated failures of voluntary agreements with the drinks industry, and the influence of the industry through its lobbying activities. We continue to press for reintroduction of the alcohol duty escalator, which was highly effective during the 5 years it was in place, and the introduction of minimum unit pricing in England, targeted at the heaviest drinkers. Results from the introduction of minimum unit pricing in Scotland, with results from Wales to follow, are likely to seriously expose the weakness of England's position. The increasing prevalence of obesity-related liver disease, the rising number of people diagnosed with type 2 diabetes and its complications, and increasing number of cases of end-stage liver disease and primary liver cancers from non-alcoholic fatty liver disease make apparent the need for an obesity strategy for adults. We also discuss the important effects of obesity and alcohol on disease progression, and the increased risk of the ten most common cancers (including breast and colon cancers). A new in-depth analysis of the UK National Health Service (NHS) and total societal costs shows the extraordinarily large expenditures that could be saved or redeployed elsewhere in the NHS. Excellent results have been reported for new antiviral drugs for hepatitis C virus infection, making elimination of chronic infection a real possibility ahead of the WHO 2030 target. However, the extent of unidentified cases remains a problem, and will also apply when new curative drugs for hepatitis B virus become available. We also describe efforts to improve standards of hospital care for liver disease with better understanding of current service deficiencies and a new accreditation process for hospitals providing liver services. New commissioning arrangements for primary and community care represent progress, in terms of effective screening of high-risk subjects and the early detection of liver disease.

UR - http://www.scopus.com/inward/record.url?scp=85058600875&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(18)32561-3

DO - 10.1016/S0140-6736(18)32561-3

M3 - Comment/debate

VL - 392

SP - 2398

EP - 2412

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 10162

ER -